Production Method 1

82087-66-9

103290-40-0

96314-26-0

Reaction Conditions

1.1 Reagents: Lithium ,  Ammonia Solvents: Ammonia

Reference

Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines

Krapcho, John; Turk, Chester; Cushman, David W.; Powell, James R.; DeForrest, Jack M.; et al, Journal of Medicinal Chemistry, 1988, 31(6), 1148-60

(2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid Raw materials

• 1H-Pyrrole-1,2-dicarboxylic acid, 2,5-dihydro-4-phenyl-, 1-(phenylmethyl) ester, (S)- (9CI)

(2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid Preparation Products

• (2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid (96314-26-0)
• (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid (103290-40-0)

• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Professional Introduction to (2S,4R)-4-Phenylpyrrolidine-2-carboxylic Acid (CAS No. 103290-40-0)

(2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid, identified by its CAS number 103290-40-0, is a compound of significant interest in the field of pharmaceutical chemistry and drug development. This molecule, characterized by its specific stereochemical configuration and aromatic substituent, has garnered attention due to its potential applications in the synthesis of bioactive molecules and the exploration of novel therapeutic pathways. The unique structural features of this compound make it a valuable scaffold for medicinal chemists seeking to design molecules with enhanced pharmacological properties.

The stereochemistry of (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid plays a crucial role in determining its biological activity. The presence of the (2S,4R) configuration suggests a high degree of specificity in its interactions with biological targets, which is a critical factor in drug design. This stereochemical arrangement is often associated with improved binding affinity and selectivity, making it an attractive candidate for further development. The pyrrolidine ring, a common motif in many bioactive compounds, contributes to the compound's overall stability and bioavailability.

In recent years, there has been growing interest in the development of molecules based on the pyrrolidine scaffold due to their diverse biological activities. Research has shown that pyrrolidine derivatives can exhibit a wide range of pharmacological effects, including anti-inflammatory, antiviral, and anticancer properties. The aromatic phenyl group in (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid further enhances its potential by contributing to hydrophobic interactions and improving binding affinity to target proteins.

The synthesis of (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid presents unique challenges due to its complex stereochemical requirements. Advanced synthetic methodologies, such as asymmetric hydrogenation and chiral resolution techniques, are often employed to achieve the desired stereochemical purity. These methods ensure that the compound retains its biological activity by maintaining the integrity of its stereocenters. The synthesis process also requires careful optimization to minimize side reactions and maximize yield, which are critical factors in large-scale production.

Current research in the field of pharmaceutical chemistry is focused on leveraging computational tools and high-throughput screening techniques to identify novel bioactive compounds. These approaches have enabled the rapid discovery and characterization of molecules with promising therapeutic potential. (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid has emerged as a key intermediate in several drug discovery programs due to its structural versatility and functional diversity. Its incorporation into more complex molecular frameworks has led to the development of novel drug candidates with enhanced efficacy and reduced toxicity.

One of the most exciting applications of (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid is in the development of targeted therapies for cancer. Preclinical studies have demonstrated that derivatives of this compound can selectively inhibit the growth of cancer cells by targeting specific enzymes and signaling pathways involved in tumor progression. The phenyl group in the molecule interacts with hydrophobic pockets on cancer-related proteins, disrupting their function and effectively inhibiting tumor growth. These findings have opened up new avenues for the development of next-generation anticancer drugs.

Another area where this compound has shown promise is in the treatment of neurological disorders. Research suggests that modifications of the pyrrolidine scaffold can lead to compounds with neuroprotective properties. The ability of these compounds to cross the blood-brain barrier makes them particularly attractive for treating conditions such as Alzheimer's disease and Parkinson's disease. By protecting neurons from oxidative stress and inflammation, these compounds have the potential to slow down disease progression and improve patient outcomes.

The pharmacokinetic properties of (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid are also subjects of intense investigation. Understanding how this compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for optimizing its therapeutic use. Advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, have been employed to study these processes in detail. This information is essential for designing formulations that enhance drug delivery and improve patient compliance.

In conclusion, (2S,4R)-4-Phenylpyrrolidine-2-carboxylic acid (CAS No. 103290-40-0) represents a significant advancement in pharmaceutical chemistry with broad applications across multiple therapeutic areas. Its unique stereochemical configuration and structural features make it a valuable building block for drug discovery programs aimed at developing novel therapeutics for cancer, neurological disorders, and other diseases. Continued research into this compound will likely uncover even more exciting applications and contribute to improving human health worldwide.

• 96314-26-0((2S,4S)-4-Phenylpyrrolidine-2-carboxylic acid)
• 3005-68-3(3-Phenylpyrrolidine-2-carboxylic acid)
• 103290-41-1(D-Proline,4-phenyl-, trans- (9CI))
• 118758-50-2((2R,3S)-3-Phenylpyrrolidine-2-carboxylic acid)
• 82087-73-8((2S,4S)-4-Benzylpyrrolidine-2-carboxylic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)